FDA approves generic versions of Lamisil

Share this article:

The FDA today approved the first generic versions of Novartis' Lamisil (terbinafine hydrochloride) tablets, used to treat nail fungus infection (onychomycosis).

The agency approved applications from multiple generic drug manufacturers for terbinafine hydrochloride tablets in 250-milligram formulations. Those generic manufacturers include: Amneal Pharmaceuticals, Apotex, Aurobindo Pharma USA, Dr. Reddy's Laboratories, Gedeon Richter USA, Genpharm, Glenmark Pharmaceuticals, InvaGen Pharmaceuticals, Mylan Pharmaceuticals, Orgenus Pharma, Roxane Laboratories, Teva Pharmaceuticals USA, Watson Laboratories and Wockhardt USA. 

Patent exclusivity for Lamisil expired on June 30.

Lamisil tablets are the 57th-best selling brand-name prescription drug in the US, the FDA said.  

In addition to terbinafine tablets, FDA also approved an application for a generic version of OTC Lamisil cream (terbinafine hydrochloride,1%) to treat athlete’s foot. The cream is manufactured by Taro Pharmaceuticals USA.

Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.